CD4 and cancer: In TAg+ tumor models, CD8+ T cells are critical in the antitumor response, demonstrated by the successful rejection of 9.27 cancer cells in both wild-type (WT) and CD4-deficient (CD4−/−) mice but not in CD8−/− or RAG1−/− mice (fig.